These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 6438639

  • 1. Intravesical chemotherapy.
    Prout GR.
    Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of superficial carcinoma of the bladder.
    Paulson DF.
    Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
    [No Abstract] [Full Text] [Related]

  • 3. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 4. Intravesical chemotherapy: how effective is it?
    Heney NM.
    Urology; 1988 Mar; 31(3 Suppl):17-9. PubMed ID: 3126591
    [Abstract] [Full Text] [Related]

  • 5. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Mar; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 6. Treatment modalities in superficial bladder cancer.
    Irwin R, Zincke H, Droller MJ, Prout GR, Soloway MS.
    Semin Urol; 1989 Feb; 7(1 Suppl 1):1-12. PubMed ID: 2499916
    [No Abstract] [Full Text] [Related]

  • 7. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
    Prout GR, Kopp J.
    Prog Clin Biol Res; 1984 Feb; 162B():397-427. PubMed ID: 6438644
    [No Abstract] [Full Text] [Related]

  • 8. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH, Bouffioux C, Sylvester R, de Pauw M.
    Prog Clin Biol Res; 1988 Feb; 269():525-37. PubMed ID: 3134663
    [No Abstract] [Full Text] [Related]

  • 9. Clinical trials in superficial and invasive bladder cancer.
    Smith PH.
    Turk J Pediatr; 1984 Feb; 26(1-4):251-63. PubMed ID: 6443168
    [No Abstract] [Full Text] [Related]

  • 10. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989 Feb; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 11. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
    Wang SH.
    Zhonghua Wai Ke Za Zhi; 1992 Jul; 30(7):410-2, 443-4. PubMed ID: 1301342
    [Abstract] [Full Text] [Related]

  • 12. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 Jul; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

  • 13. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS.
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [Abstract] [Full Text] [Related]

  • 14. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 15. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A, Gutiérrez Sanz-Gadea C, Hernández Fernández C, Mateos Torres A, Maganto Pavón E, Mayayo Dehesa T.
    Actas Urol Esp; 1985 Feb; 9(2):135-46. PubMed ID: 3925729
    [No Abstract] [Full Text] [Related]

  • 16. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988 Feb; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 17. Risk-adapted use of intravesical chemotherapy.
    Lerner SP, Au JL.
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract] [Full Text] [Related]

  • 18. Current concepts in the management of superficial bladder cancer.
    Soloway MS.
    Arch Esp Urol; 1990 Nov; 43 Suppl 2():115-21. PubMed ID: 2129003
    [No Abstract] [Full Text] [Related]

  • 19. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [Abstract] [Full Text] [Related]

  • 20. Surgery and intravesical chemotherapy in the management of superficial bladder cancer.
    Soloway MS.
    Semin Urol; 1983 Feb; 1(1):23-33. PubMed ID: 6433424
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.